Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited ( (AU:IMU) ) has issued an announcement.
Imugene Limited announced its extraordinary general meeting amid ongoing clinical studies involving over 200 dosed patients, with data readouts expected over the next year. The company has a market capitalization of A$306 million and a cash position of A$54.3 million, bolstered by a recent R&D rebate, highlighting its strong financial standing to support its innovative cancer treatment research.
More about Imugene Limited
Imugene Limited is a clinical-stage company in the immuno-oncology sector, focusing on the development of novel immunotherapies designed to activate the immune system to fight and eliminate tumors. Their platform technologies include cell therapy, oncolytic viruses, and innovative combination applications, with clinical studies underway in the US and Australia.
YTD Price Performance: 4.17%
Average Trading Volume: 164,421
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $190.5M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.
